# Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

> **NCT07353294** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 12 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma
- Lymph Node Metastasis

## Interventions

- **DRUG:** propranolol
- **DRUG:** Tislelizumab
- **DRUG:** gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07353294
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07353294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07353294, "Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07353294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*